Research Paper Volume 16, Issue 5 pp 4889—4903
5-Hydroxytryptophan acts as a gap junction inhibitor to limit the spread of chemotherapy-induced cardiomyocyte injury and mitochondrial dysfunction
Figure 4. 5-HTP ameliorates doxorubicin-induced cardiotoxicity through inhibition of gap junctions. (A) Scatter plot of KEGG enrichment analysis of down-regulated genes by H-5-HTP group; (B) Scatter plot of Reactome enrichment analysis of down-regulated genes by H-5-HTP group; (C) Relative levels of mRNA for gap junction-related genes; (D) IL-1β immunohistochemistry results, bar = 100 μm; (E) Cx43 immunofluorescence results, bar = 100 μm; (F) Fluorescence intensity of Cx43 immunofluorescence; *P < 0.05 vs. the Control group, #P < 0.05 vs. the DOX group. (L-5-HTP group: L-5-HTP+DOX; M-5-HTP group: M-5-HTP+DOX; H-5-HTP group: H-5-HTP+DOX).